BioSpace News Archive

TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business. During the year, Edesa reported favorable results from two clinical studies and achieved multiple regulatory and operational milestones for its current and upcoming drug de

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 78,576 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 44,900 shares of common stock and inducement restricted stock units, covering an aggregate of 33,676 shares of its common stock.

Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progressed following at least one, but no more than four, prior lines of therapy for metastatic disease will be discontinued due to futility based on a planned analysis conducted by an independent data monitoring committee.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) today announced the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older.

Thubrikar Aortic Valve, Inc. today announced authorization from the Competent Authority of Poland to expand the TAVI-1 CE Mark trial of the Optimum Transcatheter Aortic Valve Implantation System™ (Optimum TAVI System™).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.

Tourmaline Bio, Inc. announced that Tourmaline has been added to the NASDAQ Biotechnology Index, effective prior to market open, Monday, December 18, 2023.

Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders (“Annual Meeting”), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.

Rhythm Pharmaceuticals, Inc. announced that on December 7, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 10,500 shares of its common stock to one new employee, consisting of inducement stock options to purchase an aggregate of 7,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 3,500 shares of its common stock.